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Summary Pregabalin is a recently licensed and marketed antiepileptic drug for use
as adjunctive treatment of partial epilepsy. It acts at presynaptic calcium channels,
modulating neurotransmitter release in the CNS, properties it shares with gabapentin.
Its clinical development over the past decade has included its use in the treatment of
neuropathic pain, and generalized anxiety disorder, in addition to epilepsy. Three
multi-centre randomised, double-blind, placebo-controlled trials enrolling patients
with refractory partial epilepsy have demonstrated an antiepileptic effect of prega-
balin against placebo, as adjunctive therapy, with 31—51% of patients showing a 50%
reduction in seizure frequency. Adverse effects were dose related, the commonest
being somnolence, dizziness, and ataxia. Weight gain was seen in 14% of patients on
the highest dose of 600 mg/day. Around 9000 people have been exposed to pregabalin
in its development for all indications. No idiosyncratic reactions have been described
to date. Pregabalin may be a useful addition in the treatment of refractory partial
epilepsy. As with all new AEDs long-term follow up and post marketing surveillance is
required.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Contents
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74 K. Hamandi, J.W. SanderIntroductionFigure 1 Schematic of pregabalin mode of action. Bind-
ing to the a2-d subunit of voltage-gated calcium channels
to modulate calcium influx and hence neurotransmitter
release.Up to 70% of people diagnosed with epilepsy become
seizure free with single or combination antiepileptic
drug (AED) therapy.1 The remaining continue to have
seizures despite optimal AED therapy. Depending on
the seizure substrate a small number of these may
benefit from epilepsy surgery.2 AEDs, however,
remain the mainstay of treatment. Those in whom
seizure control remains elusive are subject to higher
doses and combinations of AEDs with subsequent
increased risk of side effects and drug—drug inter-
actions. Lifestyle implications of treatment are
therefore as important as seizure control, the pri-
mary goal of therapy being seizure reduction with
minimal side effects.
Since 1989 nine new anti epileptic drugs (AEDs)
have been licensed for the treatment of epilepsy in
the UK. These include vigabatrin, lamotrigine, gaba-
pentin, topiramate, tiagabine, oxcarbazepine,
levetiracetam and most recently pregabalin and
zonisamide. Vigabatrin has now restricted use due
to the development of visual field defects as a
chronic side effect.
Studies of any new AED are required to satisfy
regulatory authorities with regards efficacy and
safety prior to licensing.3 Ethical considerations
require that study design maintains patients on
established treatments with new AEDs as add on
therapy, hence their initial licensed use as adjunc-
tive therapy. Subsequent monotherapy licensing is
achieved after a period of post marketing surveil-
lance and recognized efficacy in clinical use. Of the
‘new’ AEDs, lamotrigine, topiramate and oxcarba-
zapine are licensed in the UK for monotherapy use. A
number of further AEDs are in the developmental
phase. These include amongst others carabersat,
lacosemide, rufinamide, safinamide, talampanel
and valrocemide.4 Therapeutic options in epilepsy
are therefore increasing rapidly and detailed knowl-
edge of the new drugs is necessary for appropriate
treatment recommendations.
Pregabalin has been in the development pipeline
for just over a decade. Its role in the treatment of
two other common conditions: neuropathic pain,5
and generalized anxiety disorder6 in addition to
epilepsy has been evaluated simultaneously. This
is timely in view of the widespread ‘‘off label’’
use of other antiepileptic drugs, for these condi-
tions. As a consequence around 9000 people have
received the drug during the clinical development
programme for all indications, totaling about 6500
patient/years exposure.
Pregabalin like gabapentin is a structural, but not
functional analogue of the neurotransmitter
gamma-aminobutyric acid (GABA). Pregabalin hasshown greater potency than gabapentin in preclini-
cal models of epilepsy and pain7 in addition to
anxiolytic properties.8 It is hydrophilic but readily
crosses the blood brain barrier. Pregabalin binds
potently to the a2-d subunit, an auxiliary protein
associated with voltage-gated calcium channels in
the CNS, attenuating depolarization-induced Ca2+
influx in nerve terminals (Fig. 1).9 This results in
reduction of glutamate,10 noradrenaline11 and sub-
stance P12 release. Pregabalin is inactive at GABAA
and GABAB receptors and it has no effect on GABA
uptake or degradation.
Pregabalin is active in a number of animal models
of epileptic seizures including maximal electro-
shock-induced tonic extensor seizures in mice and
rats,13 hippocampal kindled rats14 and threshold
clonic seizures from the convulsive agent pentyle-
netetrazol and genetic mouse models, with a
greater potency than gabapentin.7 In animal models
of spontaneous absence seizures (i.e. Wistar rats),
spike wave activity was not blocked by pregabalin7
suggesting that like gabapentin, pregabalin should
be avoided in the treatment of idiopathic general-
ized epilepsy.
Pregabalin exhibits linear pharmakokinetics.
There is no protein binding or hepatic metabolism.
It is renally excreted. No drug—drug interactions
have been identified during its development, but
pregabalin is additive in the impairment of cognitive
and motor function when taken with oxycodone (an
opiate analgesic) and may potentiate the effects
of lorazepam and alcohol.15Review of randomised-controlled trials
The efficacy and tolerability of pregabalin in the
treatment of epilepsy has been investigated in three
multi centre randomised, double-blind, placebo-
controlled trials, as adjunctive therapy in patients
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Table 1 Outline of the three double-blind randomised placebo-controlled trials of pregabalin in the treatment of
patients with refractory partial epilepsy
Trial Total daily
dose (mg/day)
Dose regime Titration Treatment N(ITT) Location
French et al.16 50 25 mg BD None 12 weeks 453 USA
150 75 mg BD Canada
300 150 mg BD
600 300 mg BD
Arroyo et al. 17 150 50 mg TDS None 12 weeks 287 Europe
600 200 mg TDS None Australia
South Africa
Beydoun et al.18 600 200 mg TDS None 12 weeks 312 USA
600 300 mg BD Canadawith refractory focal epilepsy (Table 1).16—18 A
total of 1052 patients were entered into these
studies, 758 randomized to the treatment arms
and 294 to placebo arms. Study protocols were
similar to those of other second generation AEDs
developed over the past 10 years. Patients
recruited had refractory partial seizures. An 8-
week baseline monitoring period was followed by
a 0—1-week titration phase and 12-week treat-
ment phase with placebo or drug, with the option
to continue with an open label phase. Inclusion
criteria included partial seizures refractory to
medical therapy, greater than six partial seizures
in the 8-week baseline monitoring period and no
4-week period free of seizures during baseline.
Patients were taking at least one but not more
than three AEDs. Baseline AEDs were continued
throughout the trial period. Exclusion criteria
included significant medical or psychiatric illness;
seizures caused by an underlying medical illness,
absence seizures, Lennox Gestaut syndrome or
status epilepticus in the year prior to entry (see
Table 2 for baseline characteristics).Table 2 Baseline characteristics patients recruited in
the three randomized placebo-controlled trial of preg-
abalin16—18
Age (mean
(range))
38 (12—82) years
Age at diagnosis
(mean (range))
13.7 (0—73.5) years
Duration of epilepsy
(mean (range))
25 (0.5—71.2) years
No. of seizures in
baseline period
28 days (mean/median)
24.4/11.2
Number of concomitant AEDs
1 27%
2 50%
3 23%The primary end point of the trials was seizure
reduction measured by the Response Ratio (RRatio),
a new measure in AED trials. The RRatio = [(T  B)/
(T + B)]  100, where B is the patients seizure fre-
quency during the baseline period and T the seizure
frequency during the treatment period. The RRatio
is a transformation from baseline in seizure fre-
quency that allowed the use of parametric statis-
tical methods in subgroup analyses, e.g. for
different seizure types. It ranges from 100 and
approaches +100, an RRatio of zero means no
change, 100 complete elimination of seizures,
and 33 corresponds to a 50% reduction in seizure
frequency. To obtain more clinically meaningful
units, seizure reduction on the percent change scale
were obtained by back transforming the mean RRa-
tio using the following formula, per cent chan-
ge = [(200  RRatio)/(100  RRatio)]. The utility
of these measures to clinical practice have not been
formally assessed, nor do they allow comparisons to
be made with other AEDs.
Themore traditional Responder Rate (percentage
of patients with 50% reduction on seizures during
treatment versus baseline) was a secondary end-
point, but provides an easier comparison with out-
comes in trials of other new AEDs. The results of the
studies are summarized in Figs. 2 and 3, Table 3, and
outlined below.
Study 1. Dose response study16
This multi-centre study was conducted in the US and
Canada. Four hundred and fifty-three patients (elig-
ibility 12—70 years), were randomised to one of five
treatment groups 50, 150, 300 or 600 mg/day or
placebo administered twice daily with no titration
period.16 The mean age at onset of epilepsy was 14
years, and mean duration 25 years. The baseline
seizure rate was 10 in 28 days. 49.9% of patients
were taking 2 AEDs and 19.6 taking 3. No significant
difference in seizure frequency was seen between
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Figure 3 Responder rate: percentage of patients with
50% reduction in seizures vs. baseline. PGB, pregabalin;
BD, twice day; TDS, three times day, Pbo, placebo.
Figure 2 Seizure reduction–—percentage change from
baseliney in the three randomized placebo-controlled
trials of pregabalin in the treatment of patients with
refractory partial epilepsy. PGB, pregabalin; BD, twice
day; TDS, three times day; Pbo, placebo.placebo and 50 mg/day, 7% and 12%. Thereafter,
there was a dose related reduction in seizure fre-
quency 34% at 150 mg/day, 44% at 300 mg/day and
54% at 600 mg/day. This was reflected in the respon-
der rates. At 50 mg a day responder rates were
similar to placebo, 14% (placebo) versus 15%
(50 mg/day). Subsequently, the percentage of
patients experiencing a 50% reduction in seizure
frequency reduction were, 31% at 150 mg/day,
40% at 300 mg/day, and 51% at 600 mg/day.16 With-
drawal rates due to lack of efficacy were less than
5%.16 There was also a dose related effect in dis-
continuation rates due to adverse events, significant
in the 300 mg and 600 group but not the 50 mg
group. Five patients (5.0%) withdrew from the pla-
cebo group, six (6.8%) from the 50 mg/day group,
one (1.2%) from the 150 mg/day group, 13 (14.4%)
from the 300 mg/day group, and 21 (23.6%) from the
600 mg/day group. Seventy-three percent of
patients who withdrew due to adverse events did
so in the fist two weeks of therapy. The most fre-Table 3 The most common adverse effects and associat
treatment of patients with refractory partial epilepsy
Adverse event (AE) (preferred term) Frequency (%
Pregabalin
Dizziness 28.9
Somnolence 20.8
Ataxia 13.2
Asthenia 11.2
Weight gain 10.4
Accidental injury 9.9
Headache 9.1
Amblyobia 9.0
Diplopia 8.4
Tremor 7.5
Thinking abnormal 7.0quent adverse effects were CNS related: ‘‘dizzi-
ness’’, somnolence and ataxia. Dose related
weight gain was reported, 1.1% in the 50 mg group
versus 12.4% in the 600 mg/day, with a mean weight
gain of 0.5 kg in the placebo group compared to
2.28 kg in the 600 mg/day group, however, only one
patient withdrew due to weight gain.
Study 2. Dose response study17
This study was carried out in Europe, South Africa
and Australia, and 287 patients were randomised to
treatment with either 50 mg, 600 mg/day or pla-
cebo 17. The median duration of epilepsy was 23
years and the median seizure frequency during the
8-week baseline period was 11 seizures/28 days.
There was a short titration phase, patients rando-
mised to 150 mg/day were titrated to full dose by
day 4, and those randomised to 600 mg/day wereed withdrawals in trials of pregabalin and placebo in
) Discontinuation due to AE (%)
Placebo Pregabalin Placebo
10.5 5.3 0.3
10.9 3.3 0.0
4.1 3.0 0.3
8.2 1.8 0.3
1.4 0.4 0.0
5.4 0.9 0.0
11.6 1.2 0.0
4.4 1.6 0.0
3.7 1.6 0.7
3.7 1.5 0.0
2.0 1.3 0.0
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600 mg/day were both significantly more effective
in reducing seizures compared to placebo, with
seizure reductions of 1.8% placebo, 20.6% for
150 mg/day and 47.8% for 600 mg/day. This was
reflected in the responder rates (number of patients
with 50% reduction in seizure frequency) with
43.5% in the 600 mg/day group and 6.2% in the
placebo group. The responder rate for the
150 mg/day was 14.1% which was not statistically
significant. Again CNS adverse effects were the most
commonly reported, with somnolence, dizziness
and ataxia. The withdrawal rates due to adverse
effects were 6.2% for the placebo group, 10% for the
150 mg/day group, and 18.5% for the 600 mg/day
group. Weight gain was reported in 2.1% of patients
taking placebo, 7.1% on 150 mg/day and 14.1 per-
cent taking 600 mg/day; one patient withdrew due
to weight gain.
Study 3. Twice day and three day dosing
comparison18
A third study compared the effects of twice day
and three times a day dosing of pregabalin against
placebo.18 In this study carried out in the US and
Canada, 312 patients were randomised to receive
either one of two regimens of 600 mg/day (two
divided doses (BD), or three divided doses (TDS)) or
placebo. Seventy-six percent of patients com-
pleted the 12-week study. Both dosage regimens
were significantly more effective than placebo
with a seizure reduction of 44% for the BD group
and 53% for the TDS group and 1% for the placebo
group. The corresponding responder rates were
43% for the BD group and 49% for the TDS group
and 9% for the placebo group. Again dizziness,
somnolence, and ataxia were the most frequent
adverse events. Dizziness was reported in 38% of
patients for TDS, 42% of patients for BD and 9% for
placebo.
The incidence of withdrawals due to adverse
events was 26, 19 and 7% with pregabalin BD, TDS
or placebo, respectively.
A separate report noted myoclonus in 4 of 19
patients enrolled into one of the studies.19 There
appeared a dose dependency with jerks being most
severe in the patient taking 600 mg of pregabalin a
day and jerks subsided with reduction of the drug;
EEG recoding in this patient with the highest fre-
quency of myoclonic jerks did not show any
change. All patients were also taking carbemaze-
pine at a dose that was slightly higher than those
taking this combination who did not develop jerks.
It is not clear whether the combination of prega-
balin and carbemazapine was responsible, but thefinding is in keeping with the known association
of the related gabapentin and myoclonic jerks. The
mechanism is unclear.Discussion
The results of these controlled studies suggest that
pregabalin may be effective in the treatment of
partial epilepsy. A key question is how it compares
with currently available AEDs. There are recognised
difficulties in making such comparisons with cur-
rently available evidence.20 Differences in study
design and study populations cannot be formally
accounted for. Nevertheless the design of studies
for new AEDs over the past decade has been broadly
similar. The responder rates for pregabalin (600 mg/
day) is similar than those seen in trials of other new
AEDs, levetiracetam (2000—3000 mg/day) and
topiramate (300—800 mg).21
Adverse effects were similar to other AEDs, CNS
related side effects predominated. High starting
doses or rapid titration are likely to have influenced
these. Similarly around a quarter of patients were
taking three concomitant AEDs that could increase
the likelihood of adverse symptoms. Eighty three
percent of patients from the treatment arm and 87%
from the placebo arm of those who completed the
randomized phase entered into the open label
extension. The reported weight gain again shows
similarities in the behaviour of pregabalin to gaba-
pentin. The mechanism remains unclear.
Pregabalin is available in 25, 50, 75, 100, 150, 200
and 300 mg capsules. The initial recommended
starting dose is 150 mg/day, a level at which sig-
nificant therapeutic benefit was seen in one trial.16
Nevertheless high starting doses and rapid titration
have lead to increased adverse effects with other
new AEDs and we feel that a lower stating dose than
the recommended 150 mg/day, and slow titration
would be preferable.
In conclusion, pregabalin is a CNS acting drug
structurally and functionally related to gabapentin
with greater potency than gabapentin in animal
models of partial epilepsy and other neurological
and psychiatric conditions, namely peripheral neu-
ropathic pain and anxiety. Its efficacy and tolerabil-
ity against placebo has been demonstrated in three
randomised-controlled trials in partial epilepsy.
Clinicians are likely to first use pregabalin in their
patients with refractory seizures in whom other
‘‘established’’ add on AEDs lack efficacy or are
not tolerated due to side effects. The absence of
pharmacokinetic interactions facilitate its use in
those already on multiple AEDs. Early indications
are that this is not a broad spectrum drug for
78 K. Hamandi, J.W. Sanderepilepsy, and it should be avoided or used with
caution in idiopathic generalized epilepsy and pos-
sibly Lennox Gastaut syndrome. How its greater
potency in animal models, compared to gabapentin
translates in clinical practice remains to be seen.
The next important step in assessing the place of
pregabalin in the antiepileptic armemantarium will
be post marketing surveillance and case reporting as
well as longer term retention studies.References
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